Total Payments
$572,989
2024 Payments
$24,327
Companies
45
Transactions
532
Medicare Patients
10,804
Medicare Billing
$3.5M
Payment Breakdown by Category
Research$312,003 (54.5%)
Consulting$172,236 (30.1%)
Travel$62,596 (10.9%)
Other$10,847 (1.9%)
Food & Beverage$9,142 (1.6%)
Education$6,165 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $312,003 | 113 | 54.5% |
| Consulting Fee | $172,236 | 48 | 30.1% |
| Travel and Lodging | $62,596 | 64 | 10.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,395 | 13 | 1.8% |
| Food and Beverage | $9,142 | 287 | 1.6% |
| Education | $6,165 | 4 | 1.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $367.32 | 2 | 0.1% |
| Grant | $84.20 | 1 | 0.0% |
Payments by Type
Research
$312,003
113 transactions
General
$260,986
419 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $263,030 | 74 | $0 (2022) |
| Ichnos Sciences Inc. | $102,493 | 56 | $0 (2023) |
| Celgene Corporation | $59,870 | 72 | $0 (2024) |
| Kite Pharma, Inc. | $28,767 | 26 | $0 (2023) |
| Millennium Pharmaceuticals, Inc. | $27,460 | 20 | $0 (2017) |
| F. Hoffmann-La Roche AG | $22,525 | 12 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $13,220 | 16 | $0 (2024) |
| Janssen Global Services, LLC | $12,630 | 17 | $0 (2022) |
| GENZYME CORPORATION | $8,952 | 18 | $0 (2024) |
| PFIZER INC. | $5,547 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,327 | 42 | E.R. Squibb & Sons, L.L.C. ($7,073) |
| 2023 | $17,443 | 35 | Ichnos Sciences Inc. ($6,940) |
| 2022 | $60,127 | 50 | Ichnos Sciences Inc. ($19,633) |
| 2021 | $23,215 | 22 | Ichnos Sciences Inc. ($10,405) |
| 2020 | $103,321 | 39 | Ichnos Sciences Inc. ($65,515) |
| 2019 | $205,114 | 97 | Takeda Pharmaceuticals U.S.A., Inc. ($173,660) |
| 2018 | $85,455 | 124 | Takeda Pharmaceuticals U.S.A., Inc. ($53,001) |
| 2017 | $53,987 | 123 | Millennium Pharmaceuticals, Inc. ($27,460) |
All Payment Transactions
532 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $774.97 | Research |
| Study: Phase I II Cevostamab in Prior BCMA Exposed r r Multiple Myeloma patients | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $370.06 | Research |
| Study: Phase I II Cevostamab in Prior BCMA Exposed r r Multiple Myeloma patients | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,540.00 | General |
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $141.81 | General |
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $36.37 | General |
| 12/07/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $67.29 | General |
| Category: Oncology | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $67.27 | General |
| Category: Oncology | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $28.12 | General |
| Category: Oncology | ||||||
| 12/06/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $122.57 | General |
| 12/06/2024 | AstraZeneca UK Limited | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: Oncology | ||||||
| 11/26/2024 | Secura Bio, Inc. | COPIKTRA (Drug) | Food and Beverage | In-kind items and services | $18.98 | General |
| Category: ORAL ONCOLOGIC | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $896.11 | Research |
| Study: USE OF BISPECIFIC ANTIBODIES (BsAbs) IN COMMUNITY PRACTICES: MULTIDISCIPLINARY PERSPECTIVES ON DEVELOPING LOGISTICS AND WORKFLOW FOR CYTOKINE RELEASE SYNDROME (CRS) MANAGEMENT | ||||||
| 09/28/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $39.03 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug), XPOVIO | Consulting Fee | Cash or cash equivalent | $2,037.50 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug), XPOVIO | Food and Beverage | In-kind items and services | $243.16 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $62.99 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $21.98 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug), XPOVIO | Travel and Lodging | Cash or cash equivalent | $15.50 | General |
| Category: Oncology | ||||||
| 09/24/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $128.15 | General |
| Category: Oncology | ||||||
| 09/24/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $22.59 | General |
| Category: Oncology | ||||||
| 09/23/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $9.89 | General |
| Category: Oncology | ||||||
| 08/30/2024 | IGI Inc | — | — | Cash or cash equivalent | $45.00 | Research |
| Study: ISB 1342-101 | ||||||
| 08/14/2024 | IGI Inc | — | — | Cash or cash equivalent | $90.00 | Research |
| Study: ISB 1342-101 | ||||||
| 07/24/2024 | PFIZER INC. | ELREXFIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,520.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ISB 1342-101 | Ichnos Sciences Inc. | $102,493 | 56 |
| Study of MLN4924 Plus Azacitidine in Treatment-Naive Patients With Acute Myelogenous Leukemia AML Who Are 60 Years or Older | Takeda Pharmaceuticals U.S.A., Inc. | $100,246 | 10 |
| An Open-Label, Dose-Escalation Phase 1-2 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, Administered in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Requiring Syst | Takeda Pharmaceuticals U.S.A., Inc. | $36,112 | 12 |
| An Open-Label, Dose-Escalation, Phase 1-2 Study of the Oral Formulation of MLN9708 Administered Twice-weekly in Combination with Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment | Takeda Pharmaceuticals U.S.A., Inc. | $13,558 | 2 |
| ACE-011-MDS-001 | Celgene Corporation | $11,406 | 2 |
| IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma | Takeda Pharmaceuticals U.S.A., Inc. | $8,803 | 2 |
| The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma INSIGHT | Takeda Pharmaceuticals U.S.A., Inc. | $7,444 | 3 |
| ISB 1342-101 | IGI Inc | $5,452 | 5 |
| CC-4047-MM-014 - Immune profiling of relapsed or refractory multiple myeloma patients treated with pomalidomide and low-dose dexamethasone in combination with daratumumab | Celgene Corporation | $3,048 | 1 |
| CC-4047-MM-014 | Celgene Corporation | $2,976 | 1 |
| CRB-401 A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma (CRB-401) | Celgene Corporation | $2,866 | 1 |
| 4220 - CFZ Ph3 H2H vs Velcade (2011-003) ENDEAVOR | Amgen Inc. | $1,663 | 1 |
| Immune profiling of relapsed or refractory multiple myeloma patients treated with pomalidomide and low-dose dexamethasone in combination with daratumumab (CC-4047-MM-014) | Celgene Corporation | $1,620 | 1 |
| Phase I II Cevostamab in Prior BCMA Exposed r r Multiple Myeloma patients | F. Hoffmann-La Roche AG | $1,539 | 3 |
| CRB-401 - CRB-401 A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma | Celgene Corporation | $1,326 | 1 |
| ACE-011-MDS-001 - An Open-label, Randomized, Phase 2, Parallel, Dose-Ranging, Multicenter Study of Sotatercept for the Treatment of Patients with Anemia and Low or Intermediate-1 Risk Myelodysplastic Syndromes or Non-p | Celgene Corporation | $1,281 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,257 | 1 |
| CAMMA 2: A Phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who are triple-class refractory and have received a prior anti-B-cell maturation antigen (BCMA) agent | F. Hoffmann-La Roche AG | $1,053 | 2 |
| USE OF BISPECIFIC ANTIBODIES (BsAbs) IN COMMUNITY PRACTICES: MULTIDISCIPLINARY PERSPECTIVES ON DEVELOPING LOGISTICS AND WORKFLOW FOR CYTOKINE RELEASE SYNDROME (CRS) MANAGEMENT | F. Hoffmann-La Roche AG | $896.11 | 1 |
| ACE-011-MF-PI-0005 | Celgene Corporation | $578.00 | 1 |
| Modified Kd56 Regimen in US Community Centers | Amgen Inc. | $511.84 | 2 |
| CC-4047-MM-007 - Safety and efficacy of pomalidomide, bortezomib, and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma | Celgene Corporation | $442.00 | 1 |
| 4300 - CFZ Ph1b/2 CHAMPION #1 (2012-002) | Amgen Inc. | $393.52 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 51 | 2,246 | 47,643 | $1.8M | $998,664 |
| 2022 | 61 | 2,642 | 38,907 | $1.5M | $851,177 |
| 2021 | 64 | 3,110 | 57,789 | $2.0M | $815,201 |
| 2020 | 64 | 2,806 | 52,133 | $1.7M | $860,231 |
Total Patients
10,804
Total Services
196,472
Medicare Billing
$3.5M
Procedure Codes
244
All Medicare Procedures & Services
244 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 13 | 16,020 | $951,660 | $609,095 | 64.0% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 19 | 5,606 | $332,998 | $179,369 | 53.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 37 | 197 | $37,036 | $17,448 | 47.1% |
| 83521 | Measurement of immunoglobulin light chains | Office | 2023 | 117 | 967 | $29,500 | $16,224 | 55.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 98 | 165 | $33,935 | $14,715 | 43.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 84 | 105 | $32,382 | $13,656 | 42.2% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 118 | 1,471 | $24,304 | $13,309 | 54.8% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 29 | 252 | $52,920 | $12,656 | 23.9% |
| J1442 | Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | Office | 2023 | 11 | 15,360 | $30,720 | $11,731 | 38.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 30 | 122 | $49,665 | $10,844 | 21.8% |
| 86334 | Immunologic analysis technique on serum (immunofixation) | Office | 2023 | 117 | 496 | $19,464 | $10,780 | 55.4% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 172 | 809 | $15,048 | $8,256 | 54.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 51 | 135 | $16,875 | $7,946 | 47.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 188 | 1,038 | $15,078 | $7,801 | 51.7% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 18 | 92 | $6,440 | $6,311 | 98.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 63 | 94 | $13,254 | $5,623 | 42.4% |
| 90671 | Pneumococcal conjugate vaccine, 15 valent (pcv15), for intramuscular use | Office | 2023 | 17 | 22 | $6,776 | $5,308 | 78.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 175 | 635 | $9,564 | $5,255 | 54.9% |
| 84165 | Protein measurement, serum | Office | 2023 | 117 | 496 | $9,720 | $5,186 | 53.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 28 | 117 | $21,645 | $5,079 | 23.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 26 | 28 | $7,672 | $3,615 | 47.1% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 108 | 474 | $5,424 | $2,778 | 51.2% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 20 | 190 | $11,590 | $2,768 | 23.9% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 11 | 97 | $8,573 | $1,926 | 22.5% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 20 | 22 | $3,960 | $1,867 | 47.2% |
About Dr. Jesus Berdeja, M.D
Dr. Jesus Berdeja, M.D is a Hematology & Oncology healthcare provider based in Nashville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1902842412.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jesus Berdeja, M.D has received a total of $572,989 in payments from pharmaceutical and medical device companies, with $24,327 received in 2024. These payments were reported across 532 transactions from 45 companies. The most common payment nature is "" ($312,003).
As a Medicare-enrolled provider, Berdeja has provided services to 10,804 Medicare beneficiaries, totaling 196,472 services with total Medicare billing of $3.5M. Data is available for 4 years (2020–2023), covering 244 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Nashville, TN
- Active Since 06/22/2006
- Last Updated 01/25/2012
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1902842412
Products in Payments
- ISB 1342-101 (Drug) $65,515
- Revlimid (Drug) $54,425
- NINLARO (Drug) $42,422
- Pomalyst (Drug) $18,411
- BB-2121 (Drug) $15,578
- Sotatercept (Drug) $13,265
- Yescarta (Drug) $10,200
- Ninlaro (Drug) $8,803
- Non-Covered Product (Drug) $8,734
- SARCLISA (Biological) $8,734
- ELREXFIO (Drug) $5,122
- Tecartus (Drug) $3,820
- XPOVIO (Drug) $2,320
- CARVYKTI (Drug) $2,234
- Kyprolis (Drug) $1,663
- OPDIVO (Biological) $1,616
- TASIGNA (Drug) $1,395
- Columvi (Biological) $1,140
- Kyprolis (Biological) $1,009
- Farydak (Drug) $742.72
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Nashville
Dr. Jonathan Abbas, Md, MD
Hematology & Oncology — Payments: $1.5M
Hematology & Oncology $1.5M
Kent Shih, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Alan Tan, M.d, M.D
Hematology & Oncology — Payments: $1.0M
Hematology & Oncology $1.0M
Brian Rini, Md, MD
Hematology & Oncology — Payments: $685,999
Hematology & Oncology $685,999
Dr. Krish Patel, M.d, M.D
Hematology & Oncology — Payments: $568,657
Hematology & Oncology $568,657
Dr. Robert Cornell, M.d, M.D
Hematology & Oncology — Payments: $564,553
Hematology & Oncology $564,553